ArticleBMC cancer2010
Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells.
Article in BMC cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Mitochondrial matrix protein LETMD1 maintains thermogenic capacity of brown adipose tissue in male mice.Nature communications · 2023Article
- Plumbagin binds to epidermal growth factor receptor and mitigate the effects of epidermal growth factor micro-environment in PANC-1 cells.Medical oncology (Northwood, London, England) · 2023Article
- Psoralidin inhibits osteosarcoma growth and metastasis by downregulating ITGB1 expression via the FAK and PI3K/Akt signaling pathways.Chinese medicine · 2023Article
- HGF induces oncoprotein HCCR-1 expression through the Wnt/β-catenin pathway in gastric cancer.American journal of translational research · 2022Article
- Silencing of microRNA-135b inhibits invasion, migration, and stemness of CD24Cancer cell international · 2020Article
- HCCR-1 is a Novel Prognostic Indicator for Gastric Cancer and Promotes Cell Proliferation.Journal of Cancer · 2019Article
- Overexpression of NaOncotarget · 2018Article
- Rotundarpene inhibits TNF-α-induced activation of the Akt, mTOR, and NF-κB pathways, and the JNK and p38 associated with production of reactive oxygen species.Molecular and cellular biochemistry · 2017Article
- Article
- Human cervical cancer oncogene-1 over expression in colon cancer and its clinical significance.International journal of clinical and experimental medicine · 2015Article
- The role of human cervical cancer oncogene in cancer progression.International journal of clinical and experimental medicine · 2015Review
- Quantitative detection of the human cervical cancer oncogene for monitoring the minimal residual disease in acute leukemia.Experimental biology and medicine (Maywood, N.J.) · 2015Article
- Uncovering the pathogenesis and identifying novel targets of pancreatic cancer using bioinformatics approach.Molecular biology reports · 2014Article
- Insulin/Insulin-Like Growth Factor-1 Pathway in Barrett's Carcinogenesis.Clinical and translational gastroenterology · 2013Article
- Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma.Oncology letters · 2012Article
- Clinical implication of elevated human cervical cancer oncogene-1 expression in esophageal squamous cell carcinoma.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman cervical cancer oncoprotein 1 (HCCR-1), reported as a negative regulator of p53, is over-expressed in a variety of human cancers. However, it is yet unknown whether HCCR-1 plays any role in pancreatic cancer development. The aim of this study was to investigate the effect of epidermal growth factor on the expression of HCCR in pancreatic cancer cells, and to explore if PI3K/Akt/mTOR signaling pathway mediated this expression.
methodsA polyclonal antibody against HCCR protein was raised by immunizing Balb/c mice with the purified recombinant protein pMBPc-HCCR. Tissue samples were constructed on a tissue chip, and the expression of HCCR was investigated by immunohistochemistry assay and Western blotting. Pancreatic cell line, PANC-1 cells were stably transfected with plasmids containing sense-HCCR-1 fragment and HCCR siRNA fragment. MTT and transwell assay were used to investigate the proliferation and invasion of stable tansfectants. The specific inhibitor of PI3K and mTOR was used to see if PI3K/mTOR signal transduction was involved in the induction of HCCR gene expression. A Luciferase assay was used to see if Akt can enhance the HCCR promoter activity.
resultsHCCR was up-regulated in pancreatic tumor tissues (mean Allred score 4.51+/-1.549 vs. 2.87+/-2.193, P<0.01), especially with high expression in poorly differentiated pancreatic cancer. The growth of cells decreased in HCCR-1 siRNA transfected cells compared with vector transfectants. The number of invasion cells was significantly lower in HCCR-1 siRNA transfected cells (24.4+/-9.9) than that in vector transfectants (49.1+/-15.4). Treatment of PANC-1 cells with epidermal growth factor increased HCCR protein level in a dose- and time-dependent manner. However, application of LY294002 and rapamycin caused a dramatic reduction of epidermal growth factor-induced HCCR expression. Over-expression of exogenous constitutively active Akt increased the HCCR promoter activity; in contrast, dominant negative Akt decreased the promoter activity.
conclusionsEGF-induced HCCR-1 over-expression is mediated by PI3K/AKT/mTOR signaling which plays a pivotal role in pancreatic tumor progression, suggesting that HCCR-1 could be a potential target for cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.